- No significant difference in recurrence-free survival (RFS) between TICE and Connaught Bacillus Calmette-Guerin (BCG) strains used in combination with interferon in BCG-naïve and BCG-failure patients with nonmuscle-invasive bladder cancer.
Why this matters
- There has been limited investigation on substrain comparative efficacy, though differences in phenotypes and antigenicity have been reported.
- BCG naïve patients who received TICE BCG had RFS rates of 80% at 3 mo, 64% at 1 y, and 54% at 2 y.
- Connaught BCG patients had RFS rates of 83%, 70%, and 65%, respectively.
- Univariable analysis found duration of disease >2 y (P=.04), multifocal tumors (P=.04), tumor size >5 cm vs <0.5 cm (P<0.01), and TICE BCG (P=.05) were associated with increased risk for recurrence.
- After controlling for duration of disease, tumor focality, and tumor size, strain was no longer an independent risk factor (P=.28).
- BCG-failure patients who received TICE BCG had 3-mo, 1-y, and 2-y RFS rates of 79%, 53%, and 44%, respectively.
- Connaught BCG patients had rates of 81%, 58%, and 47%, respectively.
- BCG strain had no significant prognostic value for recurrence (P=.53).
- Post hoc analysis of a phase 2 study (N=901).
- Funding: None disclosed.
- Post hoc analysis.